Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
Board Comprises Six Members with Notable Contributions to the Fields of Oncology and Immunology BERKELEY, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in
View HTML
Toggle Summary Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B Data Presented at 2018 American Diabetes Association Annual Meeting BERKELEY, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation
View HTML
Toggle Summary Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
BERKELEY, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Michael Ostrach , Dynavax’s Chief Financial Officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL.
View HTML
Toggle Summary Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Overall Response Rate ( ORR ) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of SD -101 Combination showed Similar Rates of Immune-related Adverse Events as Seen with KEYTRUDA Monotherapy 2mg SD-101 Dose Selected
View HTML
Toggle Summary Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels BERKELEY, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies
View HTML
Toggle Summary Dynavax Reports First Quarter 2018 Financial Results
Update on Initial Progress of HEPLISAV-B ® Commercial Launch Conference Call to be Held at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the first quarter ended March 31, 2018 .
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , May 07, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the “Committee”) approved the grant of inducement stock options to purchase an aggregate of 79,000
View HTML
Toggle Summary Dynavax to Host First Quarter 2018 Financial Results Conference Call
BERKELEY, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018 , and host a conference call that day to review the results
View HTML
Toggle Summary Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
HEPLISAV-B Now Meets a Critical Reimbursement Requirement for Many Insurance Plans BERKELEY, Calif. , April 23, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention (CDC) published the Advisory Committee of
View HTML
Toggle Summary Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR BERKELEY, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today
View HTML